Mounjaro Blood Clots Lawsuit [2024 Update]

The Mounjaro Blood Clot Lawsuit is an active lawsuit

See If You Qualify

Individuals are filing lawsuits against the maker of Mounjaro, Eli Lilly and Company, alleging the drug may put people at an increased risk of developing blood clots and Deep Vein Thrombosis (DVT). Litigation against the manufacturer is ongoing with new lawsuits continuing to be filed across the country. Individuals who have been diagnosed with blood clots, deep vein thrombosis, or other dangerous health conditions are encouraged to seek legal counsel to determine if they are eligible for compensation.

About the Mounjaro Blood Clot Lawsuit:

Mounjaro and Blood Clots Overview

A recent analysis of the safety of GLP-1s found individuals taking the drug may be at a significantly increased risk of developing deep vein thrombosis (DVT). DVT occurs when a blood clot forms in the deep veins of the body, particularly the legs. DVT can be extremely dangerous if a blood clot breaks loose, traveling to the lungs and causing a pulmonary embolism. Individuals taking Mounjaro or other GLP-1s should be monitored closely for blood clots and deep vein thrombosis.

Research Links GLP-1 Agonists to Heightened Risk of Blood Clots

A 2021 study titled “Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials” published in the Endocrine Journal (Volume 68, Issue 6, pages 739-742) found that GLP-1s increase the risk of deep vein thrombosis (DVT) by 266%. The objective of the study was to assess the risk of serious adverse events (SAEs), including blood clots, in patients with type 2 diabetes who are taking GLP-1s.

The meta-analysis included 21 trials (10 PIONEER and 11 SUSTAIN trials) involving 12,260 semaglutide users and 14,176 comparators and determined that GLP-1s significantly increase the risk of deep vein thrombosis up to 266% (RR 3.66, 95% CI 1.09–12.25; I2 = 0). Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using random-effects and fixed-effects models. 

While there was no mention of a specific increased risk of pulmonary embolism (PE), the increased risk of DVT raises concerns that the potentially fatal condition could develop. DVT is a leading cause of PE. Furthermore, the study did not address long-term safety, as most trials had a follow-up duration of one year or less and some findings lacked sufficient statistical power due to wide confidence intervals. 

Additional research is needed to examine whether weight loss associated with Mounjaro contributes to the risk of blood clots, it is believed that the increased DVT risk associated with GLP-1s may be tied to diarrhea and dehydration linked to use of the drug. These side effects could increase blood viscosity.

While Mounjaro generally has a good safety profile, the significant increase in DVT risk calls for careful monitoring, especially in patients at higher risk for blood clots. Physicians prescribing Mounjaro should monitor for signs of blood clots and ensure proper hydration to reduce risks. Caution is advised when prescribing the GLP-1 to patients with a predisposition to blood clots.

What Are Blood Clots From Mounjaro?

Mounjaro is used to improve blood sugar control in adults with type 2 diabetes. It is a GLP-1 receptor agonist, which stimulates insulin release and lowers blood sugar levels. Blood clots from Mounjaro refer to thrombi that can occur as a side effect of GLP-1s. Research shows that Mounjaro can increase the risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Blood clots can block blood flow in veins or arteries, leading to severe complications such as heart attack or stroke.

Blood clots from GLP-1 receptor agonists used to control blood sugar in adults with type 2 diabetes can occur as a side effect, increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). Symptoms include swelling and pain in the legs, sudden shortness of breath, and chest pain. Recent studies have raised concerns about Mounjaro’s potential side effects, including an increased risk of DVT.

Individuals taking Mounjaro or other GLP-1 receptor agonists should be monitored closely for DVT, particularly considering that people with type 2 diabetes have an increased risk of developing plaque buildup in the arteries, which can lead to dangerous blood clots. 

General Symptoms of Blood Clots:

• Pain, discomfort, and redness in the affected area.
• Unexplained pain in the arms, legs, or other parts of the body.

Conditions Related to Blood Clots:

• Deep Vein Thrombosis (DVT): Swelling, pain, and tenderness in the affected area, often the leg.
• Pulmonary Embolism (PE): Sudden shortness of breath, chest pain, and rapid heart rate.

Understanding how GLP-1 drugs cause DVT involves studying changes in blood composition or vessel walls that promote clotting under certain conditions. Research is ongoing to determine the precise relationship between Mounjaro and blood clots. Patients taking Mounjaro should be aware of blood clot symptoms and seek immediate medical attention if they experience any signs. Staying informed and vigilant about potential side effects is crucial when using this medication.

How Does Mounjaro Cause Blood Clots?

Mounjaro might cause blood clots through mechanisms like altered blood coagulation, inflammation, dehydration, and changes in blood flow. Other factors to consider include patient-specific risk factors such as pre-existing conditions, lifestyle factors, and genetic predispositions. Research continues into how GLP-1s such as Mounjaro may increase a person’s risk for developing blood clots and related conditions such as deep vein thrombosis. 

Potential Mechanisms and Patient-Specific Risk Factors for Blood Clot Formation with GLP-1s:

• Altered Blood Coagulation: Drugs like Mounjaro may affect the balance between procoagulant and anticoagulant factors, increasing the tendency for blood to clot.
• Inflammation: Some GLP-1 receptor agonists may cause inflammation in blood vessels, making them more susceptible to clot formation.
• Dehydration: Gastrointestinal side effects such as nausea, vomiting, and diarrhea caused by GLP-1 receptor agonists can lead to dehydration, thickening of the blood, and increasing the risk of clot formation.
• Changes in Blood Flow: Drugs like Mounjaro may influence blood flow by altering blood vessel tone and function, contributing to clot formation, especially in individuals with underlying vascular conditions.
• Pre-existing Conditions: Cardiovascular disease, history of clotting disorders, and other pre-existing conditions can increase the risk of blood clots when taking Mounjaro.
• Lifestyle Factors: Obesity, prolonged inactivity, and a sedentary lifestyle are key risk factors for developing blood clots.
• Genetic Predispositions: Certain genetic factors may predispose individuals to a higher risk of blood clots when taking Mounjaro.

There are many factors that may contribute to how GLP-1s increase a person’s risk of blood clots including that people with type 2 diabetes who take Mounjaro may have an increased risk of plaque buildup in their arteries, potentially leading to blood clots. There is ongoing research into how GLP-1 drugs like Mounjaro contribute to blood clot formation, but continuous monitoring is critical for patients who may be at risk.

Can Mounjaro Cause Blood Clots in Your Lower Extremities?

A 2021 study found that people taking GLP-1s like Mounjaro were 3.66 times more likely to develop deep vein thrombosis (DVT). Other research also links the drug to blood clots in the legs, including DVT and other thromboembolic events. Individuals taking Mounjaro should seek immediate medical attention if blood clot symptoms are detected, such as leg swelling, pain, tenderness, or redness. This is critical for individuals who have additional risk factors such as a history of blood clots, prolonged immobility, obesity, family history, inherited clotting disorders, age over 60, and diabetes.

Symptoms of Deep Vein Thrombosis (DVT) in Legs:

• Swelling: Sudden swelling in one leg is a common sign.
  
• Pain or Tenderness: Pain often starts in the calf, feeling like cramping or soreness, and may extend to the foot or thigh.
  
• Red or Discolored Skin: Skin over the affected area may become red or have a bluish hue.
  
• Warmth: The skin around the clot area can feel warm to the touch.
  
• Visible Veins: Veins near the skin’s surface might become more visible or engorged.
  
• Leg Fatigue: A feeling of heaviness or tiredness in the affected leg.
  
• Difficulty Walking: Pain and swelling can make walking or standing more difficult.

If taking Mounjaro and experiencing symptoms of a blood clot, such as swelling, pain, or redness in the leg, seek immediate medical attention. Individuals with risk factors for developing blood clots should be monitored closely while taking the drug, as they may be more likely to develop the condition. Risk factors for developing blood clots include a history of blood clots, prolonged immobility, being overweight, a family history of blood clots or clotting disorders, conditions like Factor V Leiden mutation, being over 60, and having diabetes.

Mounjaro Side Effects: Blood Clots, Deep Vein Thrombosis, and Pulmonary Embolisms

GLP-1s such as Mounjaro are used to improve blood sugar control in adults with type 2 diabetes, but they may increase a person’s risk of developing blood clots. Blood clots are clumps of blood that have changed from a liquid to a gel-like or semisolid state and can form in veins or arteries. They can potentially obstruct blood flow and lead to complications such as deep vein thrombosis (DVT) and a pulmonary embolism (PE). 

Symptoms of DVT include swelling and pain in the legs, while a pulmonary embolism may present with sudden shortness of breath and chest pain. Individuals taking Mounjaro or another GLP-1 should monitor for these symptoms, particularly if they have additional risk factors such as prolonged immobility, dehydration, or underlying health conditions. Preventative measures may include staying sufficiently hydrated while taking the drug and moving regularly. 

Blood Clot Side Effects:

• Deep Vein Thrombosis (DVT): A clot that occurs in a deep vein, usually in the legs. Symptoms include swelling, pain, tenderness, and redness, often in the calf. If a part of the clot breaks off, it can travel to other parts of the body. Risk Factors include prolonged immobility, dehydration, a history of clotting disorders, and cardiovascular conditions.
• Pulmonary Embolism (PE): This occurs when a blood clot (often from a DVT) travels to the lungs and blocks a pulmonary artery. Symptoms include sudden shortness of breath, chest pain, rapid heart rate, lightheadedness, and coughing up blood. A pulmonary embolism may be life-threatening and requires immediate medical attention. PEs carry the same risk factors as DVT. 
• General Blood Clots: Symptoms of blood clots include pain, swelling, redness, warmth, and visible veins. Risk Factors include dehydration (possibly from gastrointestinal side effects of Mounjaro), prolonged immobility, and underlying health conditions.

Individuals taking Mounjaro should drink plenty of fluids, especially if experiencing gastrointestinal side effects. They should also avoid prolonged periods of immobility, such as taking breaks to move around if sitting for long periods to help prevent blood clots.

While all DVTs and PEs are types of blood clots, not all blood clots are DVTs or PEs. DVT refers to clots in deep veins, and PE refers to a clot that has traveled to the lungs. Patients using Mounjaro should be aware of these side effects and take steps to mitigate risks.

The Difference Between Deep Vein Thrombosis and Pulmonary Embolisms

Both Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) are types of Venous Thromboembolism (VTE), which involves blood clots that form in veins and can cause serious health issues.

Deep Vein Thrombosis (DVT) is defined as a blood clot that forms in a deep vein, usually in the lower extremities. It is most common in the legs, thighs, pelvis, and sometimes arms. Symptoms include pain, swelling, and redness in the affected leg or weakness in the leg. The primary risk is that part of the clot can break off and travel to the lungs, leading to a pulmonary embolism.

Pulmonary Embolism (PE) occurs when a piece of a DVT clot breaks off, travels to the lungs, and causes a blockage in an artery. Most PEs are caused by clots that originate from the deep veins of the legs (DVT). Symptoms include chest pain, shortness of breath, and syncope (fainting). A PE can be life-threatening, causing damage to the lungs and other organs due to reduced blood flow and oxygen levels.

Differences Between DVT and PE:

• Location: A DVT is a clot that forms in deep veins, usually the legs, while a PE is a clot that travels to and lodges in the arteries of the lungs.
  
• Symptoms: A DVT presents with localized symptoms such as swelling, pain, and redness in the leg. Conversely, PE has systemic symptoms affecting the lungs and overall oxygenation, including shortness of breath, chest pain, and a rapid heart rate.
• Risk and Severity: For a DVT, the risk lies primarily in the potential for the clot to travel to the lungs. The risk of PE is immediate and potentially fatal if not treated promptly.
• Treatment: DVTs are treated with anticoagulant medications, compression stockings, and lifestyle changes to prevent further clots. PEs are also treated with anticoagulant drugs but may also require thrombolytic therapy (clot dissolvers) and surgical intervention in severe cases.

Are Blood Clots Common Among Mounjaro Users?

A 2021 meta-analysis of the SUSTAIN and PIONEER trials found that GLP-1 users have a 266% increased risk of developing deep vein thrombosis. The study’s methodology involved 21 randomized trials with over 26,000 participants. While research is ongoing to determine why GLP-1s like Mounjaro may put patients at an increased risk of developing blood clots, potential mechanisms include the higher incidence of diarrhea and dehydration associated with the use of the drug, leading to increased blood viscosity. Individuals taking Mounjaro should use caution, particularly if they have risk factors that may predispose them to blood clots and related conditions. 

How to Avoid Blood Clots While Taking Mounjaro

If you are taking Mounjaro, there are specific preventative measures that you should take, including staying hydrated to avoid dehydration, engaging in regular physical activity to prevent prolonged immobility, using compression stockings if advised by your healthcare provider, and regular monitoring for blood clot symptoms such as swelling and pain in the legs. Mounjaro patients should also maintain regular check-ups with their healthcare provider to manage pre-existing conditions and ensure that their medication is adequately adjusted as necessary.

Other GLP-1 Drugs Linked to Blood Clots

It is not only Mounjaro patients who may be at an increased risk for developing blood clots. Individuals taking other GLP-1 drugs, such as Ozempic, Wegovy, and Rybelsus, should also be monitored by a healthcare provider for blood clots and DVT symptoms while taking the medication.

Who Qualifies to File a Mounjaro Blood Clot Lawsuit?

If you are diagnosed with blood clots while taking Mounjaro, you may be eligible for compensation. However, you must meet certain eligibility requirements to qualify. It is essential to consult with an attorney as quickly as possible after your diagnosis to ensure the best possible outcome in your claim. 

Eligibility requirements for a Mounjaro blood clot lawsuit:

• Ability to prove that you received Mounjaro treatments.
• Diagnosis of blood clot-related conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).
• Age 75 or younger.
• Your condition required an emergency room visit or hospitalization.

You may be ineligible for compensation in a Mounjaro blood clot lawsuit if you had previous blood clot-related surgeries or treatments or are receiving current treatments for other unrelated serious health conditions.

Mounjaro patients who have been diagnosed with blood clots or a related condition are encouraged to contact an experienced lawyer due to state-specific statutes of limitations. While the criteria mentioned above are guidelines, the best way to determine eligibility is to consult with a Mounjaro lawyer as early in the process as possible. Timely legal consultation preserves the right to file for potential compensation.

How to File a Mounjaro Blood Clot Lawsuit

It is essential to follow specific steps to ensure the best possible outcome in your Mounjaro blood clot lawsuit. An attorney can help you manage the legal process and ensure you receive the compensation you deserve if you qualify for a lawsuit.

Step-by-Step Process for Filing a Mounjaro Blood Clot Lawsuit:

1. Determine Eligibility: The first step in a Mounjaro blood clot lawsuit is determining whether you qualify to take legal action. Mounjaro attorneys offer free case reviews to verify lawsuit eligibility. Once retained, an attorney will manage the legal process, including ensuring that your claim adheres to any state-specific deadlines or statutes of limitations when filing. During the initial consultation, your attorney will review your medical records and Mounjaro usage history to ensure eligibility. 
2. Collect Evidence: Once eligibility has been verified, you will need to collect evidence like medical records and witness testimonies that will help substantiate your claim. An attorney can help determine the evidence you need to support your case. It is imperative to supply your legal team with all of your health information and supporting documentation in a timely manner.
3. File the Claim: The next step in a Mounjaro blood clot lawsuit is filing the claim in the appropriate courthouse. Your attorney will ensure that all legal requirements are met and that your lawsuit is filed timely.
4. Negotiations and Discovery Phase: Once the case is filed, it will enter into the discovery phase. During this time, each party will exchange information, take depositions, and conduct research to help strengthen their case. Your attorney will also handle all settlement negotiations.
5. Trial: Your case may be set for trial if a settlement cannot be reached. During the trial, the case is presented in court. Depending on the outcome of the trial, your case may be appealed.
6. Post-trial: Your attorney or the defendant may appeal the decision after trial. Your legal team will handle all aspects of this process. It is important to stay in constant communication with your lawyer and to allow the law firm to represent you.

Mounjaro Blood Clot Settlement and Payout Amounts

There is no standardized settlement value of Mounjaro blood clot lawsuits as many cases are still in their infancy. Multiple factors may determine the amount of money you receive, including the extent of your damages and losses, whether you are eligible for punitive damages, and if you have retained an experienced attorney. 

The estimated settlement value for cases involving severe blood clot-related injuries or death is $400,000 to $700,000, with the primary determining factor being the damages claimed and their calculated value. 

Types of Losses Covered:

• Healthcare Costs: For claims related to blood clot injuries such as deep vein thrombosis (DVT) or pulmonary embolism (PE), possible costs include emergency care, lab tests, treatments for blood clots, hospitalization, and recovery medications. However, costs may vary based on location and severity of side effects.
• Lost Wages: Compensation for time off work due to Mounjaro effects or treatments, as well as coverage for diminished earning potential.
• Pain and Suffering: Variable damages awarded for emotional distress.
• Punitive Damages: Allowed in some states to punish defendants for negligence or wrongful actions. Allegations generally include Eli Lilly not adequately warning about Mounjaro’s side effects. Punitive damages might increase settlements for those with significant blood clot-related injuries.

An attorney can help maximize compensation by understanding the full range of available damages. They can also provide guidance on required documentation to demonstrate value and will negotiate to ensure a fair settlement is offered.

Have You Experienced Blood Clots While Taking Mounjaro?

Have you been diagnosed with blood clots while taking Mounjaro? The attorneys at King Law are well-versed in product liability and dangerous drug cases. Contact our office today to schedule a free consultation to determine whether you are eligible to pursue legal action against the drug’s manufacturer. 

Contact a Mounjaro Blood Clot Lawyer

Contact King Law today to speak with an attorney experienced in Mounjaro and GLP-1 blood clot lawsuits. Our legal team will help determine your eligibility for compensation and manage the legal process. Do not wait until it is too late, as state-specific statutes of limitations may limit the amount of time you have to file a claim. 

Frequently Asked Questions (FAQs)